Trifluridine

• 

  Subject Areas on Research

  • Herpes simplex keratitis in patients with acquired immune deficiency syndrome. 
  • Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.